Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-024021
Filing Date
2025-08-14
Accepted
2025-08-14 16:08:44
Documents
54
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 936767
2 EX-31.1 ex31-1.htm EX-31.1 11700
3 EX-31.2 ex31-2.htm EX-31.2 11612
4 EX-32.1 ex32-1.htm EX-32.1 10483
  Complete submission text file 0001641172-25-024021.txt   4271031

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE envb-20250630.xsd EX-101.SCH 38170
6 XBRL CALCULATION FILE envb-20250630_cal.xml EX-101.CAL 43476
7 XBRL DEFINITION FILE envb-20250630_def.xml EX-101.DEF 146360
8 XBRL LABEL FILE envb-20250630_lab.xml EX-101.LAB 303296
9 XBRL PRESENTATION FILE envb-20250630_pre.xml EX-101.PRE 220575
56 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 516008
Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38286 | Film No.: 251218971
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)